Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - Sarepta Therapeutics is entering 2026 with a strong financial position and significant opportunities ahead [3] - The company will discuss three main topics: the untapped potential of its four approved therapies, the opportunities in its next-generation siRNA pipeline, and its solid financial footing [4] Group 1: Approved Therapies - Sarepta has four approved therapies that present a significant untapped opportunity [4] Group 2: Next-Generation siRNA Pipeline - The company is focusing on the outsized opportunity associated with its next-generation siRNA pipeline [4] Group 3: Financial Position - Sarepta is in great financial shape, which will enable the company to pursue its ambitions and capitalize on the opportunities available [4]